To include your compound in the COVID-19 Resource Center, submit it here.

Agios reports Phase I data for ivosidenib/azacitidine combo in AML

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) reported data from a Phase I trial in 11

Read the full 133 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE